UK Markets closed

Omeros Corporation (OMER)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
15.81-0.01 (-0.06%)
At close: 4:00PM EDT
Sign in to post a message.
  • d
    dukeandduke
    Anyone here interested???? ben, Billyboy, Onyx??

    Job Posting
    Head of Investor Relations



    Head of Investor Relations





    Good things are happening at Omeros!

    Come join our Corporate Team!





    Working closely with the CEO, VP Finance, Legal, and other members of the executive leadership team, this position will strategically plan, develop, manage, coordinate, and execute on a comprehensive and pro-active investor relations initiative focusing on establishing and maintaining awareness and understanding of Omeros and its many programs and value propositions within the investor community (both individual and institutional) regarding corporate goals and objectives, company developments, and financial results.
    The ideal candidate will play a critical role in fostering relationships with the investment community, helping shape, articulate and manage the investment story of Omeros and convey key messages about the company’s innovative drug pipeline and technology, as well as the company’s strategy and vision.
  • b
    ben
    If the CEO really cared about those inflicted with these diseases he would have partnered on some trials but he slow walks them making a very nice living for himself but not much else. If he died what impact would it have on the company?
  • N
    No Way Out
    Not that it will matter to the “market”, but the OMS906 results are huge - once-monthly SC dosing will open up a lot of markets/indications and speed up both clinical trials and market adoption once approved.
  • b
    ben
    Only four more month's until we hear from the FDA, maybe we get an I-SPY COVID-19 trial update by then. Not much else that I see anyone see any catalysts.
  • B
    Billy Boy
    GD can throw all the giberish PRs he wants. This share price keeps falling then that will be what the discussion can move to. It should be thrashed right in to and out of ASM. The job is not done until the $14 secondary buyers are underwater too. How will GD raise any money then of any amount? This will firmly place the writing on the wall for GD to get dismissed. And when he does, yup, up goes the shareprice. The vote does not help, GD and his insiders and board have voting power to push that result around in my opinion. So some short term pain helps the long term gain. Pulling for substantial share price failure to be demonstrative to GD's failure.
  • b
    ben
    Onyxpig, Based on the CEO's track record if he was to get FDA approval for IGAN how long do you think it will take, 3, 4, 5 years or something else?
  • T
    The real Onyxpig
    Well, Dr. Perales must not have hit it out of the park rehashing the same data we’ve heard for 2 years now. Where’s the PR on his podium presentation, Greg?
  • n
    noah
    The Proxy tally for 2017 OMER stock give away had huge gains in NY, Chicago, Houston, but lost it in Atlanta, Milwaukee, Phoenix, and Detroit. Greg is blaming it on the machines. OMER share holders need to know.
  • N
    No Way Out
    Look what happened to AEMD based on the results of two COVID patients. With OMER’s short interest and results, the Reddit crowd should be all over it?
  • B
    Billy Boy
    OH BOY! OMER will do the BofA Napa conference, oh goodie. GD can start working the next secondary virtually from his wine cellar on Mercer Island, while chugging down Napa wine that we paid for!
  • B
    BagholderHumper
    LOL! GOMER releasing phase ONE results for its MASP-3 inhibitor??? What is it they say about being "a day late and a dollar short":

    https://alexion.com/our-research/pipeline

    Yeah, Akexion's factor D blocker -- ALEX2050 -- is ALREADY in TWO phase TWO trials for PNH and renal diseases.

    PLUS, Biocryst is ALREADY advancing its factor D blocker:

    https://ir.biocryst.com/news-releases/news-release-details/biocrysts-oral-factor-d-inhibitor-bcx9930-advancing-pivotal

    "BioCryst’s Oral Factor D Inhibitor, BCX9930, Advancing to Pivotal Trials in PNH Following Successful Proof of Concept Trial

    —Following doses of 400 mg bid or 500 mg bid of oral BCX9930, 100 percent of treatment-naïve patients and 83 percent of C5 inadequate response patients were transfusion-free—

    —Mean hemoglobin increased from 8.3 g/dL to 11.8 g/dL in treatment-naïve patients and from 8.9 g/dL to 12.2 g/dL in C5 inadequate response patients, demonstrating control of hemolysis—

    —Pivotal trials in PNH and proof of concept trials in renal complement-mediated disease expected to begin in 2H 2021"

    Yeah, who CARES what happens to "CFD" when you can actually be EFFECTIVE at treating REAL PATIENTS!

    Not to WORRY though! MAYBE Alexion and Biocryst will leaves some CRUMBS behind for Omeros to clean up!

    ROFLMAO!!!
  • b
    ben
    The CEO's top priority has been and continues to be taking care of the CEO. Not one partner for any of their trials. The CEO stated years ago they had 5 shots on goal and to date nothing.
  • b
    ben
    Question submitted to Omeros for the ASM. When did the FDA contact Omeros about the BLA and what was discussed? Why was more data supplied and why wasn't it submitted with the BLA?
  • J
    Jan
    Did anyone hear the annual meeting conference call?
  • r
    roberta
    I-spy trails has been ongoing for more than 2 1/2 months. I would assume that futility analysis must have been done by now will be done very shortly. If the company is informed are they obligated to inform the share holders ASAP? This would seem to be a very major material event. Any thoughts?
  • b
    ben
    Omeros Announces Preliminary Results from Phase 1 Clinical Trial of OMS906
    BUSINESS WIRE 8:45 AM ET 6/9/2021
  • O
    OMER LONG
    I see the grand red short circus ring leader is at it again!! Pomerantz the ambulance chasers of the stock market world bring a new low level meaning to the word attorney.
  • n
    noah
    Volume is running ahead over 98 % above the 50 day average volume and OMER is right on schedule. Buying more right here. link : https://research.investors.com/stock-charts/nasdaq-omeros-corp-omer.htm?cht=pvc&type=daily
  • G
    Greg
    Keep you focus on what will save lives and help mankind.
    [1] Narso approval Oct 17, or sooner, and with adequate launch supplies, I would assume price negotiations are already underway, with the relevant parties.
    [2] The Narso MAA application, to the EMA, should be submitted by Mid-June, and approval from the EU may very well come by year end.
    [3] Very good chance we see some I-SPY Covid results by Mid-June, and those results could be best in class.
    [4] OMS 906 phase 1 results should be out by Sept. A once monthly subcutaneous complement pathway drug, as a follow-on to Narso, would enhance our buyout value tremendously.
    [5] IGaN trial enrollment greatly delayed by Covid (N=280), so likely no results until late Q1, 2022.
    [6] Once approval is in hand, for TMAs, a substantial capx raise, north of $30/share, should take place, enabling a full phase 2/3 Narso trial in Lupus.
    [7] I was surprised by Greg's emphasis on GPR174 for cancer, and am hopeful we see an IND, by July. A broad based onco therapy, highly synergistic with many types of cancer treatments, might be worth five times the current MC, by itself.
    Last, with a broad, and extremely promising pipeline, OMER is very deeply undervalued, here, and will be back in no time.